SynthesisFrontiers in oncology2025
Prognostic value of the HALP score in breast cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Prognostic Value of Hemoglobin, Albumin, Lymphocyte, and Platelet Score in Locally Advanced Nasopharyngeal Carcinoma.Cancer medicine · 2026Article
- Development and internal validation of a nomogram for predicting neoadjuvant therapy efficacy in breast cancer based on the HALP score.Translational cancer research · 2026Article
- PIV, PNI and HALP score for predicting pathological complete response in breast cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Machine learning-based prognostic model integrating preoperative HALP score and lactate dehydrogenase for predicting postoperative recurrence of prostate cancer.World journal of surgical oncology · 2026Article
- Composite CA15-3, LDH, and Albumin Index as a Predictor of Survival in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The present research is a meta-analysis aimed at quantifying the influence of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score on the overall survival (OS) and disease-free survival (DFS) in breast cancer patients. The objective of this research is to examine the prognostic significance of the HALP score in breast cancer patients and evaluate its predictive performance for survival outcomes. Methods: This research was conducted adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We retrieved PubMed, EMBASE, Web of Science, Cochrane Library, and Google Scholar for studies relevant to the link between the HALP score and the prognosis of breast cancer up to July 3, 2025. The quality of the studies was appraised with Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) and the Newcastle-Ottawa Scale (NOS). MetaDiSc 1.4, Stata SE 18, and Review Manager 5.4 were leveraged to examine the risk of bias and to conduct statistical analysis. Results: Among 971 studies, nine fulfilled the inclusion criteria, encompassing a total of 4,560 individuals. An increased HALP score was linked to favorable OS (HR = 0.61, 95% CI 0.39-0.97, p < 0.05). No statistically significant association was noted between the HALP score and DFS in breast cancer patients. The area under the summary receiver operating characteristics (SROC) curve (AUC) of the HALP score for predicting pathological complete response (pCR) was 0.57. Conclusion: Elevated HALP scores may represent a prognostic biomarker for favorable survival outcomes in breast cancer patients. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/myprospero identifier CRD420251031999.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.